Gregory R Pond

Statistical and analytical approaches for assessing biomarkers: new approaches, new technologies, with the same-old rigor for evaluation.

Peter A Kavsak, Matthew P A Henderson, Gregory R Pond, 2012, Clinical biochemistry.

Methods to improve the estimation of time-to-event outcomes when data is de-identified.

Gregory R Pond, Samantha-Jo Caetano, David Dawe, 2019, Statistics in medicine.

The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy

Gregory R Pond, Ian F Tannock, Andrew J Armstrong, 2011, Cancer.

Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials

Gregory R Pond, G. Pond, S. Welch, 2010, Clinical trials.

The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.

Gregory R Pond, Klaus Zerres, G. Pond, 2002, Journal of the American Society of Nephrology : JASN.

Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.

Gregory R Pond, Arnoud J Templeton, Andrew J Armstrong, 2014, Clinical genitourinary cancer.

Phase 1 trial design: is 3 + 3 the best?

Gregory R Pond, G. Pond, L. Siu, 2014, Cancer control : journal of the Moffitt Cancer Center.